Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 131B 194,400B 113B 106B 96.39B 181B 12,494B 184B 1,241B 486B 6,259B 491B 480B 20,822B P/E 2026 *
30.4x
P/E 2027 * 24.9x
Enterprise Value 116B 173,214B 101B 94.3B 85.89B 161B 11,132B 164B 1,105B 433B 5,577B 437B 428B 18,553B EV / Sales 2026 *
8.83x
EV / Sales 2027 * 7.7x
Free-Float
99.79%
Yield 2026 *
-
Yield 2027 * -
1 day-2.78%
1 week-3.85%
Current month+5.72%
1 month+3.83%
3 months+21.96%
6 months+8.34%
Current year+14.91%
1 week 7,860
Extreme 7860
8,325
1 month 7,320
Extreme 7320
8,385
Current year 6,115
Extreme 6115
8,590
1 year 4,985
Extreme 4985
8,590
3 years 4,815
Extreme 4815
8,590
5 years 4,815
Extreme 4815
8,590
10 years 4,815
Extreme 4815
8,590
Manager TitleAgeSince
Chief Executive Officer 53 2020-03-31
Director of Finance/CFO 57 2019-04-09
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 66 1997-12-31
Chairman 70 2012-04-30
Director/Board Member 57 2015-06-17
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%-3.85% - - 131B
+0.25%-3.96%+68.73%+120.06% 1,055B
+0.78%+0.21%+48.53%+50.78% 632B
+0.35%+0.95%+21.11%+66.86% 442B
+0.58%-3.12%+39.61%+40.13% 351B
+0.68%-1.51%+23.69%+38.67% 290B
+1.06%-1.64%-0.75%+9.31% 243B
+1.00%+0.52%+41.46%+58.95% 227B
-0.53%-5.39%-16.36%-53.54% 200B
+0.40%+4.40%+17.36%+81.59% 172B
Average +0.30%-1.44%+27.04%+45.87% 401.39B
Weighted average by Cap. +0.60%-1.87%+39.37%+64.37%

Financials

2026 *2027 *
Net sales 13.19B 19,622B 11.39B 10.68B 9.73B 18.29B 1,261B 18.55B 125B 49.07B 632B 49.52B 48.45B 2,102B 14.58B 21,697B 12.59B 11.81B 10.76B 20.23B 1,394B 20.51B 138B 54.26B 699B 54.76B 53.57B 2,324B
Net income 4.31B 6,405B 3.72B 3.49B 3.18B 5.97B 412B 6.05B 40.88B 16.02B 206B 16.16B 15.81B 686B 5.22B 7,762B 4.5B 4.23B 3.85B 7.24B 499B 7.34B 49.54B 19.41B 250B 19.59B 19.16B 831B
Net Debt -14.24B -21,187B -12.29B -11.53B -10.51B -19.75B -1,362B -20.03B -135B -52.98B -682B -53.47B -52.31B -2,269B -18.44B -27,429B -15.92B -14.93B -13.6B -25.57B -1,763B -25.93B -175B -68.6B -883B -69.22B -67.72B -2,938B
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
26-08-14 ARS 7,860.00 -2.78% 914
26-08-13 ARS 8,085.00 -1.94% 2,120
26-08-12 ARS 8,245.00 -0.36% 1,922
26-08-11 ARS 8,275.00 +1.22% 1,778
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
515.55USD
Average target price
563.12USD
Spread / Average Target
+9.23%

Quarterly revenue - Rate of surprise